Cheng Vicki, Sayre Eric C, Cheng Vienna, Loree Jonathan M, Gill Sharlene, Murphy Rachel A, Howren Alyssa, De Vera Mary A
The Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.
Collaboration for Outcomes Research and Evaluation, Vancouver, British Columbia, Canada.
BMJ Oncol. 2025 Apr 1;4(1):e000690. doi: 10.1136/bmjonc-2024-000690. eCollection 2025.
Individuals with colorectal cancer (CRC) have an increased risk of mental disorders, yet mental healthcare utilisation has not been adequately examined. We evaluated mental healthcare utilisation and receipt of minimally adequate treatments for anxiety and/or depression among individuals with and without CRC.
We used administrative health databases from British Columbia, Canada, comprised of individuals with CRC and individuals without CRC, matched (1:1 ratio) on age, sex and incident mental disorder(s) (ie, occurring after CRC diagnosis/matched date). Primary outcomes were minimally adequate antidepressant pharmacotherapy (≥84 days' supply) and psychological (≥4 services) treatment.
Among individuals with CRC, 1462 had incident anxiety (mean age 64.6±12.5 years, 59.2% females), 4640 had incident depression (mean age 66.3±12.3 years, 51.2% females). Approximately one in four individuals with CRC were diagnosed with anxiety (23.4%) and/or depression (23.2%) in the first year after CRC diagnosis. Minimally adequate antidepressant pharmacotherapy (36.2%) and psychological treatment (15.9%) for anxiety were significantly lower in CRC patients than in those without CRC (pharmacotherapy adjusted OR (aOR) 0.74; 95% CI 0.61, 0.88; psychological treatment aOR 0.74; 95% CI 0.58, 0.95). Similar findings were observed for depression (pharmacotherapy aOR 0.81; 95% CI 0.74, 0.90). Among individuals with CRC, mental healthcare utilisation persisted up to 10 years post-mental disorder diagnosis.
Individuals with CRC receive less mental health treatment for anxiety and/or depression, compared with those without CRC. Findings raise awareness for the need for ongoing mental healthcare throughout and beyond CRC.
结直肠癌(CRC)患者患精神障碍的风险增加,但对其精神卫生保健利用情况的研究尚不充分。我们评估了CRC患者与非CRC患者的精神卫生保健利用情况以及焦虑和/或抑郁的最低充分治疗的接受情况。
我们使用了加拿大不列颠哥伦比亚省的行政卫生数据库,其中包括CRC患者和非CRC患者,并根据年龄、性别和新发精神障碍(即CRC诊断/匹配日期后发生的)进行了(1:1比例)匹配。主要结局是最低充分的抗抑郁药物治疗(供应≥84天)和心理治疗(≥4次服务)。
在CRC患者中,1462人患有新发焦虑症(平均年龄64.6±12.5岁,女性占59.2%),4640人患有新发抑郁症(平均年龄66.3±12.3岁,女性占51.2%)。在CRC诊断后的第一年,约四分之一的CRC患者被诊断为焦虑症(23.4%)和/或抑郁症(23.2%)。CRC患者中焦虑症的最低充分抗抑郁药物治疗(36.2%)和心理治疗(15.9%)显著低于非CRC患者(药物治疗调整后的比值比(aOR)为0.74;95%置信区间为0.61,0.88;心理治疗aOR为0.74;95%置信区间为0.58,0.95)。抑郁症的情况类似(药物治疗aOR为0.81;95%置信区间为0.74,0.90)。在CRC患者中,精神卫生保健利用在精神障碍诊断后持续长达10年。
与非CRC患者相比,CRC患者接受的焦虑和/或抑郁的精神卫生治疗较少。研究结果提高了人们对CRC患者整个病程及之后持续精神卫生保健需求的认识。